Spotlight on our research at ESMO Congress 2025
06 Oct 2025
Friday 17 October marks the beginning of the ESMO Congress 2025. Researchers from the MRC Clinical Trials Unit at UCL and our partners will showcase the latest work from our prostate cancer clinical trials.
The ESMO Congress brings together oncologists, researchers, clinicians, and professionals from around the world to discuss the latest advancements in cancer research and treatment. This year’s event will take place from Friday 17 – Tuesday 21 October in Berlin, Germany, and virtually.
Details of the presentations and posters featuring the STAMPEDE, RAMPART, and ICON8B trials and the STOPCAP meta-analysis are summarised in the tables below. All times are local to Berlin.
Oral presentations
|
Date |
Time (CEST) |
Session Title |
Title |
Speaker |
|
Friday 17 October |
14-05-14:10
|
Mini-oral: GU tumours, prostate, penile and testis
|
Effects of prostate radiotherapy (RT) on synchronous, metastatic, hormone-sensitive prostate cancer (mHSPC): STOPCAP meta-analysis of individual participant data (IPD)
|
Peter Godolphin |
|
Saturday 18 October |
8:30-10:00 |
Proffered Paper session 2: GU tumours, renal & urothelial |
First results from RAMPART: An international phase 3 randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL |
James Larkin |
|
Sunday 19 October |
15:45-15:55 |
Proffered paper session: Gynaecological cancers |
ICON8B: GCIG Phase III Randomised Trial Comparing First-line Weekly Dose-Dense Chemotherapy + Bevacizumab To Three-Weekly Chemotherapy + Bevacizumab In High-Risk Stage III-IV Epithelial Ovarian Cancer (EOC): Final Overall Survival (OS) Analysis |
Andrew Clamp |
Posters
|
Date |
Poster title |
Presenter |
|
Saturday 18 October
|
ICON8B: GCIG Phase III Randomised Trial Comparing First-line Weekly Dose-Dense Chemotherapy + Bevacizumab to Three-Weekly Chemotherapy + Bevacizumab in High-Risk Stage III-IV Epithelial Ovarian Cancer (EOC): Quality-of-Life Outcomes |
Sarah Blagden |
|
Exploring the Influence of Adjuvant Immune Checkpoint Inhibition on Health-Related Quality of Life in Renal Cell Carcinoma: A Qualitative Sub study within the RAMPART Trial |
Sophie Merrick |
|
|
On-treatment serum prostate specific antigen (PSA) and metastatic burden at treatment start: landmark analysis of 7129 patients starting long-term androgen deprivation (ADT) and randomised in the STAMPEDE platform protocol |
Laura Murphy, Mahaz Kayani |
|
|
Utilising the CHAARTED and STAMPEDE2 criteria in the Prostate Specific Membrane Antigen Positron Emission Tomography (PSMA PET) era: Implications on outcomes in metastatic prostate cancer (mPC) |
Hoda Abdel-Aty |
Further information